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Summary
Background Cytotoxic chemotherapy is generally ineffective in patients with hepatocellular carcinoma. We assessed 
the intravenous perfusion of doxorubicin-loaded nanoparticles in patients with hepatocellular carcinoma in whom 
previous sorafenib therapy had failed.
Methods We did a multicentre, open-label, randomised, controlled phase 3 trial at 70 sites in 11 countries. Patients 
with hepatocellular carcinoma with one or more previous systemic therapies, including sorafenib, were randomly 
assigned to receive 30 mg/m² doxorubicin-loaded nanoparticles (30 mg/m² group), 20 mg/m² doxorubicin-loaded 
nanoparticles (20 mg/m² group), or standard care using a computer-generated randomisation list prepared by the 
funder and stratified by geographic region. Patients in the experimental groups received perfusion of the drug every 
4 weeks and those in the control group received any systemic anticancer therapy (except sorafenib) as per investigator 
decision. The primary endpoint was overall survival in the intention-to-treat population. Safety was assessed in the 
population of patients who received at least one dose of their assigned treatment. This trial is registered with 
ClinicalTrials.gov, number NCT01655693.
Findings Between June 15, 2012, and Jan 27, 2017, 541 patients were screened, of whom 144 were excluded and 
397 were randomly assigned to one of the groups (133 to the 30 mg/m² group; 130 to the 20 mg/m² group; and 134 to 
the control group). Median follow-up was 22·7 months (IQR 11·2–34·9). After pooling the doxorubicin groups for the 
efficacy analysis, median overall survival was 9·1 months (95% CI 8·1–10·4) in the pooled doxorubicin-loaded 
nanoparticles group and 9·0 months (7·1–11·8) in the control group (HR 1·00 [95% CI 0·78–1·28], two-sided 
p=0·99). 227 (94%) of 242 patients who received doxorubicin-loaded nanoparticles and 100 (75%) of 134 patients in 
the control group had at least one treatment-emergent adverse event. The most common drug-related grade 3 or 4 
treatment-emergent adverse events were neutropenia (25 [10%] of 242 treated with doxorubicin-loaded nanoparticles 
and eight [6%] of 134 in the control group), asthenia (six [2%] and four [3%]), and thrombocytopenia (three [1%] and 
ten [7%]). Six (2%) patients treated with doxorubicin-loaded nanoparticles and one (1%) of those in the control group 
were deemed by investigators to have had a drug-related death. Serious adverse events occurred in 74 (31%) patients 
who received doxorubicin-loaded nanoparticles and 48 (36%) in the control group.
Interpretation Doxorubicin-loaded nanoparticles did not improve overall survival for patients with hepatocellular 
carcinoma in whom previous sorafenib treatment had failed.
Funding Onxeo.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Introduction
The treatment of hepatocellular carcinoma follows 
guidelines based on the Barcelona Clinic Liver Cancer 
(BCLC) staging system.1 Surgical resection, trans­
plantation, and thermoablation are potential curative 
therapies for patients with early­stage hepatocellular 
carcinoma, whereas chemoembolisation is recom mended 
as a palliative option for intermediate­stage hepatocellular 
carcinoma. For patients with advanced hepatocellular 
carcinoma, or with intermediate stage disease that is no 
longer a candidate for chemo embolisation, systemic 
strategies based on oral tyrosine kinase inhibitors such as 
sorafenib as first­line treatment2,3 and regorafenib as 
second­line treatment4 provide a clinically significant 
improvement in overall survival. Lenvatinib is non­
inferior to sorafenib as first­line treatment5 and 
cabozantinib is efficacious as second­line or third­line 
treatment.6 Ramucirumab, a monoclonal anti body 
targeting vascular endothelial growth factor receptor 2, 
has shown efficacy in the subgroup of patients with 
hepatocellular carcinoma who have concentrations of 
alpha­fetoprotein of at least 400 ng/mL after sorafenib 
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treatment failure,7 whereas ramucirumab did not 
show any significant benefit in non­selected patients 
with hepatocellular carcinoma.8 All other systemic drugs 
in phase 3 trials showed no efficacy in this population.9–16 
Further, radio embolisation with yttrium­90 has not shown 
superiority to sorafenib in a randomised phase 3 study in 
patients with advanced hepatocellular carcinoma or in 
those with intermediate hepatocellular carcinoma in 
whom chemo embolisation has failed.17,18 The best observed 
overall survival in a systemic setting was for sorafenib 
followed by regorafenib (median 26·0 months [95% CI 
22·6–28·1]).19 More effective systemic therapies are 
needed to increase overall survival of patients with 
advanced hepatocellular carcinoma.
To date, no phase 3 trials of cytotoxic chemotherapy 
for hepatocellular carcinoma have shown signs of 
efficacy. Doxorubicin was a potential candidate, but the 
administration of free doxorubicin is associated with 
high morbidity in cirrhosis;20 it also did not show any 
additive or synergistic effects when added to sorafenib.21 
Doxorubicin­loaded nanoparticles in the liver 
overwhelm the efflux pumps encoded by multiple 
drug resistance genes.22,23 A phase 1–2 trial suggested a 
potential benefit of doxorubicin­loaded nano particles 
on overall survival of patients with hepato cellular 
carcinoma, although the trial was prematurely stopped 
because of lung toxicity associated with doxorubicin­
loaded nanoparticles injected by the hepatic arterial 
route.24 Preclinical data from Wistar rats showed that 
this lung toxicity was reduced when doxorubicin­loaded 
nanoparticles were infused over 2 h.24 Thus, here, we 
assessed the efficiency of doxorubicin­loaded nano­
particles admin istered by a 6 h intravenous infusion in 




This multicentre, open­label, randomised, controlled 
phase 3 trial was done at 70 sites in 11 countries in 
Europe, the USA, the Middle East, and North Africa. 
The trial was approved by each centre’s ethics 
committee or institutional review board and complied 
with Good Clinical Practice guidelines, the Declaration 
of Helsinki, and applicable local laws. The protocol is 
available online.
Patients
Eligibility criteria were age of at least 18 years; 
hepatocellular carcinoma confirmed by pathological or 
non­invasive assessment according to the American 
Association for the Study of Liver Diseases or European 
Association for the Study of the Liver as per protocol 
criteria;1 at least one measurable lesion by Response 
Evaluation Criteria in Solid Tumors (RECIST), version 1.1; 
BCLC stage B (intermediate) or C (advanced) ineligible 
for surgical resection, liver transplantation, local ablation, 
or chemoembolisation;1 receipt of one or several previous 
systemic lines of treatment, including sorafenib if 
stopped at least 2 weeks before randomisation; Child–
Pugh score of A5 to B7; Eastern Cooperative Oncology 
Group (ECOG) performance status of 0 or 1; normal 
laboratory results (platelets ≥50 000 cells per µL, 
neutrophils ≥1000 cells per µL, haemoglobin ≥10 g/dL, 
serum aminotransferases less than five times upper limit 
of normal [ULN], alkaline phosphatase less than 
five times ULN, and serum bilirubin <35 µmol/L), and 
adequate cardiac (normal left ventricular ejection 
fraction) and pulmonary functions (oxygen saturation 
≥95%). Exclusion criteria were untreated hepatitis B; 
previous malignancy without complete remission in the 
Egypt (Prof A S Saad MD); 
Fondazione Istituto di Ricovero 
e Cura a Carattere Scientifico 
Ca’ Granda—Ospedale 
Maggiore Policlinico, Milano, 
Italy (Prof M Colombo MD); CHU 
de Clermont-Ferrand—Hôpital 
Estaing, Clermont-Ferrand, 
France (Prof A Abergel MD); CHU 
Jean Minjoz, Besançon, France 
(C Richou MD); National Liver 
Institute, Menoufyia 
University, Menoufyia, Egypt 
(Prof I Waked MD); Penn State 
Cancer Institute 
Milton S Hershey Medical 
Center, Hershey, PA, USA 
(Prof N S Yee MD); Onxeo, Paris, 
France (A Molé PhD, P Attali MD, 
B Vasseur MD); and eXYSTAT, 
Malakoff, France 
(J Le Boulicaut MSc)
Correspondence to: 
Prof Philippe Merle, Hepatology 
Unit, Croix Rousse Hospital, Lyon 
69004, France 
philippe.merle@chu-lyon.fr
See Online for appendix
Research in context
Evidence before this study
We searched PubMed for phase 3 randomised controlled 
studies of advanced inoperable hepatocellular carcinoma, 
published between Jan 1, 2000, and Feb 4, 2018, and in English. 
We used the search terms “hepatocellular carcinoma” AND 
“randomized trial” AND “chemotherapy” OR “doxorubicin”. Our 
search showed that no cytotoxic chemotherapy has improved 
survival in a previous randomised controlled phase 3 trial in 
patients with advanced hepatocellular carcinoma, except the 
small study published by Lai and colleagues in 1988. However, 
although free doxorubicin was shown to be effective in terms of 
overall survival, this drug has never become the standard of care 
for advanced hepatocellular carcinoma because of the weak 
evidence (small sample size) and the high toxicity in patients 
with cirrhosis (sepsis, mucositis, and cardiotoxicity).
Added value of this study
The results of RELIVE show that treatment with 
doxorubicin-loaded nanoparticles, which overrides multiple 
mechanisms of drug resistance-related chemoresistance, did 
not result in a significant improvement in overall survival 
compared with best standard of care in patients with disease 
progression on sorafenib alone or with other subsequent 
systemic treatment lines. The secondary endpoints of 
progression-free survival, time to progression, disease 
control, and overall tumour response also showed no 
improvement.
Implications of all the available evidence
This phase 3 trial of doxorubicin-loaded nanoparticles 
demonstrates the absence of a benefit in overall survival for 
patients with advanced hepatocellular carcinoma in whom 
sorafenib treatment had failed. These findings are in contrast 
with preclinical and phase 1 or 2 clinical studies that had 
positive results with this treatment for hepatocellular 
carcinoma. The absence of more effective therapies is an unmet 
clinical need, but so far, chemotherapy has been clearly 
demonstrated to be ineffective and toxic in these patients.
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past 5 years; HIV infection; hepatocellular carcinoma on 
transplanted liver; risk of variceal bleeding; previous 
cumulative dose of more than 300 mg/m² doxorubicin; 
ongoing immuno suppressive treatment; unstable 
medical or surgical conditions, particularly uncontrolled 
diabetes, that might disrupt study participation; un­
controlled systemic infection; life expectancy less than 
2 months; receipt of an experimental drug in another 
clinical trial in the past 30 days; and unwillingness or 
inability to use two forms of contra ception for 6 months 
after final study drug administration. All patients 
provided written informed consent.
Randomisation and masking
Patients were randomly assigned to receive either 
30 mg/m² doxorubicin­loaded nanoparticles (30 mg/m² 
group) or 20 mg/m² doxorubicin­loaded nanoparticles 
(20 mg/m² group) or standard care (1:1:1) using a 
computer­generated randomisation list prepared by the 
funder. This list was stratified by geographic region 
(Europe, USA, or Middle East and North Africa) using 
blocks (size 6). Investigators, patients, and the funder 
were unmasked to treatment assignment in this open­
label trial. However, independent central review as 
per RECIST, version 1.1, and data review by the data 
review committee before database lock were performed 
blindly. The assignment of number and code for patient 
identification ensured patient anonymity.
Procedures
In both experimental groups, doxorubicin­loaded 
nanoparticles were delivered by intravenous perfusion 
every 4 weeks with a maximum allowed cumulative dose 
of doxorubicin of 550 mg/m². Patients assigned to the 




 77 progressive disease
 8 death
 11 serious adverse event
 4 adverse event
 1 withdrew consent
 3 aggravation of liver dysfunction
 3 non-compliance
 6 case report form unclear
541 patients assessed for eligibility
144 excluded
 70 met liver function exclusion criteria
 21 met respiratory function exclusion criteria
 14 met hepatocellular carcinoma exclusion criteria
 13 met cardiac exclusion criteria
 5 serious adverse event
 12 unknown
 9 other*
133 allocated to 30 mg/m² doxorubicin-loaded
 nanoparticles (ITT population)
13 did not receive allocated
 intervention
397 enrolled in the trial




 91 progressive disease
 8 death
 2 serious adverse event
 2 adverse event
 2 withdrew consent
 3 aggravation of liver dysfunction
 1 protocol deviation
 1 non-compliance
 1 lost to follow-up
 7 case report form unclear
130 allocated to 20 mg/m² doxorubicin-loaded
 nanoparticles (ITT population)
8 did not receive allocated
 intervention




 58 progressive disease
 12 death
 11 serious adverse event
 3 adverse event
 20 withdrew consent
 7 non-compliance
 3 protocol deviation
 1 lost to follow-up
 15 case report form unclear
134 allocated to standard care (ITT population)
Figure 1: Trial profile
Data cutoff was May 28, 2017. ITT=intention to treat. *Includes one concomitant cancer, four non-compliance, two patient withdrawal, one previous other cancer, 
and one previous cumulative dose of doxorubicin. 
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standard care control group received any systemic 
anticancer therapy (except sorafenib) according to the 
centre’s practice and the decision of the principal 
investigator at that centre, being aware that any type of 
these systemic therapies had not shown efficacy in 
phase 3 trials at the time of randomisation. In all groups, 
patients received best supportive care. Treatment 
continued until disease progression as defined by 
RECIST, version 1.1, or clinical progression, death, 
unacceptable toxicity, withdrawal of consent by the 
patient, or decision by the principal investigator. Patients 
were followed up for tumour assessments every 8 weeks. 
Treatment could be continued beyond progression at the 
decision of the principal investigator. To prevent the 
occurrence of acute respiratory adverse events that we 
observed in our phase 1–2 trial,24 perfusion of 
doxorubicin­loaded nanoparticles was done over 6 h 
intravenously with safety measures (premedication with 
methyl prednisolone 32 mg orally and one antihistamine 
drug given 24 h and 1 h before perfusion and 24 h after 
perfusion). Respiratory symptoms and oxygen saturation 
were continuously monitored during the 6 h of 
perfusion: in case of dyspnoea or oxygen saturation 
decrease from 95% or more to 93% or less, the infusion 
rate was reduced by half (to a 12 h infusion) without 
changing the total dose; in case of persistence of 
dyspnoea beyond 1 h or oxygen saturation decrease to 
90% or less, perfusion was immediately and definitively 
stopped. Safety was monitored continuously throughout 
the study and patients had safety assessments every 
4­week treatment cycle. Blood tests were assessed every 
2 weeks. Adverse events were graded using National 
Cancer Institute Common Terminology Criteria for 
Adverse Events, version 4.03.
Outcomes
The primary endpoint was overall survival, defined as the 







Men 224 (85%) 117 (87%)
Women 39 (15%) 17 (13%)
Age, years 67 (60–73) 66 (61–72)
Geographical region
Europe 237 (90%) 119 (89%)
USA 5 (2%) 3 (2%)
Middle East or North 
Africa
21 (8%) 12 (9%)
Race
White 242 (92%) 125 (93%)
Black 5 (2%) 3 (2%)
Asian 5 (2%) 3 (2%)
Other 11 (4%) 3 (2%)
ECOG performance status
0 150 (57%) 70 (52%)
1 108 (41%) 63 (47%)
2 5 (2%) 1 (1%)
Macrovascular invasion 92 (35%) 46 (34%)
Extrahepatic disease 152 (58%) 83 (62%)
Alpha-fetoprotein of at 
least 400 ng/mL
108 (41%) 63 (47%)
Child–Pugh class*
A5 118 (45%) 60 (45%)
A6 105 (40%) 54 (40%)
B7 29 (11%) 17 (13%)
Greater than B7 11 (4%) 3 (2%)
Barcelona Clinic Liver Cancer stage
A (early) 0% 0%
B (intermediate) 71 (27%) 34 (25%)
C (advanced) 192 (73%) 100 (75%)
Liver cirrhosis (investigator 
assessed)
192 (73%) 103 (77%)






(Continued from previous column)
Cause of hepatocellular carcinoma†
Alcohol use 124 (47%) 68 (51%)
Hepatitis C 79 (30%) 38 (28%)
Unknown 39 (15%) 16 (12%)
Non-alcoholic 
steatohepatitis
34 (13%) 23 (17%)
Hepatitis B 24 (9%) 13 (10%)
Other 26 (10%) 7 (5%)
Number of previous systemic therapies (including sorafenib)
One (only sorafenib) 205 (78%) 99 (74%)
Two 47 (18%) 26 (19%)
Three or more 11 (4%) 9 (7%)
Reason for sorafenib interruption
Tumour progression 174 (66%) 96 (72%)
Intolerance to sorafenib 79 (30%) 35 (26%)
Other 10 (4%) 3 (2%)
Duration of sorafenib 
treatment, months
4·1 (2·4–9·3) 4·9 (2·6–8·7)
Daily sorafenib 
dose, months
722 (458–800) 800 (600–800)
Previous locoregional treatments before sorafenib‡
Surgical resection 89 (34%) 40 (30%)
Percutaneous ablations 50 (19%) 24 (18%)
Transarterial 
chemoembolisation
150 (57%) 78 (58%)
External beam 
radiotherapy
29 (11%) 9 (7%)
Data are n (%) or median (IQR). ECOG=Eastern Cooperative Oncology Group. 
*The Child–Pugh system describes liver disease severity: patients are divided into 
classes A–C. †Patients may have more than one cause. ‡Patient can be counted 
more than once in case of multiple treatments.
Table 1: Baseline characteristics
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Secondary endpoints were safety, and overall survival for 
patients with Child–Pugh score A, progression­free 
survival (defined as time from randomisation to 
radiological or clinical disease progression or death), the 
proportion of patients achieving an objective response 
(defined as a complete or partial response), and the 
proportion of patients achieving disease control (defined 
as complete response, partial response, or stable disease 
maintained for ≥8 weeks). Responses to treatment were 
assessed using RECIST (version 1.1), with independent 
central review. Safety was assessed by adverse events, 
laboratory abnormalities, vital signs, chest x­ray, and left 
ventricular ejection fraction by cardiac echography and 
electro cardiography.
Exploratory endpoints were progression­free survival 
and objective response as assessed by investigators and 
time to progression (time from randomisation to 
radiological or clinical disease progression) assessed by 
independent central review per RECIST version 1.1.
Statistical analysis
At study initiation in 2011, the initial sample size 
calculation was done on the basis of an estimated median 
survival of 6·6 months in the control group and 
10·9 months in the experimental groups (hazard ratio 
[HR] 0·60); an accrual period of 36 months; and a one­
sided α level of 2·5%. The required sample size to 
achieve a 90% power was 130 patients per group (for the 
two tests of the two doses at a 5% level).
In 2016, Bruix and colleagues4 published the results of 
a phase 3 trial of regorafenib, with a median overall 
survival of 7·8 months (95% CI 6·3–8·8) in the placebo 
group. The revised power of the estimated required 
sample size for our study in view of these new results 
and according to our accrual period of 54 months would 
be decreased from 90% to 58%.
Considering these results, study feasibility, and the need 
for results in this serious, life­threatening disease, the 
statistical analysis plan was amended after validation by 
the US Food and Drug Administration (July 24, 2017) and 
signed off by the scientific committee (Aug 25, 2017) 
before database lock (Aug 28, 2017). The revised 
statistical analysis plan pooled the two doxorubicin­loaded 
nanoparticle groups; assuming a median overall survival 
in the control group of 8 months, and aiming for a hazard 
ratio of 0·69, the required total sample size to achieve 
85% power to compare the experimental groups with 
control (two­sided α of 5%) was 348 patients (116 patients 
in the control group and 232 patients in the pooled 
experimental group). We expected recruitment to take 
55 months, with 6 months of follow­up after the last 
inclusion (total follow­up 61 months), and around 10% of 
patients to be lost to follow­up. Thus the recalculated total 
sample size was 390 patients. The analysis was planned 
for when 285 events (deaths) occurred. For the primary 
efficacy endpoint of overall survival and the secondary 
endpoint of progression­free survival, the groups were 
compared using a non­stratified log­rank test. The HR for 
overall survival and its 95% CI were calculated using the 
stratified Cox model.
The primary analysis was done in the intention­to­
treat (ITT) population, defined as all patients who had 
been randomly assigned to a group; safety analyses 
included all patients who received at least one dose of 
the study drug. The study was overseen by an 
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HR=0·95 (95% Cl 0·72–1·26); two-sided p=0·74
B
Figure 2: Kaplan–Meier analysis of overall survival
(A) Intention-to-treat population. (B) Child–Pugh A subpopulation. HR=hazard ratio.
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assess the primary endpoint of overall survival in the 
ITT population and the secondary endpoints of overall 
survival in the subpopulation of patients with Child–
Pugh score A and progression­free survival and objective 
response in the whole population and Child–Pugh 
score A subpopulation, we used a hierarchical sequential 
closed­test procedure to control the overall type I error 
rate of 5%, with the following sequence: overall survival 
in the ITT population, overall survival in the Child–Pugh 
A subpopulation, progression­free survival in the Child–
Pugh A subpopulation, and objective response in the 
Child–Pugh A subpopulation. If the closed­test 
procedure fails, all other analyses will be presented as 
exploratory.
We did a sensitivity analysis using a Cox model 
adjusting for predefined selected prognostic factors. We 
first analysed these prognostic factors in separate 
univariate analyses and then in multivariate analysis. 
More specifically, we tested each potential predictor in a 
Cox model in which the considered predictor was the only 
covariate included (treatment was not included in the 








   <65
   ≥65
Sex
   Women
   Men
Geographical region
   Europe or USA
  North Africa and Middle East
Race
   White
   Asian
   Other
ECOG performance status
   0
   >0
Child–Pugh
   A
   B
Macroscopic vascular invasion
   No
   Yes
Extrahepatic spread
   Yes
Intrahepatic spread
   Yes
Alpha-fetoprotein concentration, ng/mL
   ≥400
   <400
Number of previous treatments
     1
   >1
Anticancer therapy
   Yes
Last reason for sorafenib discontinuation
   Progression
   Intolerance
Previous sorafenib within 10 weeks*
   Yes
Alcohol use
   Yes
Hepatitis C virus
   Yes
Non-alcoholic steatohepatitis
   Yes
Hepatitis B virus
   Yes
Treatment group
   Doxorubicin 20 mg/m²











































































































































































































Favours controlFavours pooled doxorubicin
Figure 3: Forest plot of overall survival in predefined subgroups
*Exposure for at least 20 days at a concentration of at least 400 mg and discontinuation less than 10 weeks before randomisation. ECOG=Eastern Cooperative Oncology Group. n=events. N=group 
size. NE=not estimable. 
Articles
www.thelancet.com/gastrohep   Published online April 3, 2019   http://dx.doi.org/10.1016/S2468-1253(19)30040-8 7
less than 0·10 for the multivariate analysis. We then 
included the selected predictors in a multivariate Cox 
model (treatment not included in the model) and further 
selected them with a backward selection procedure 
eliminating covariates with a p value above 0·10 in 
presence of the other covariates. We then introduced 
treatment and well known predictors (macroscopic 
vascular invasion, extrahepatic spread, Child–Pugh, 
hepatitis B virus infection, and alpha­fetoprotein) as an 
additional covariate in the reduced model obtained at the 
end of the backward selection procedure. We tested the 
covariate by treatment interactions by adding in a separate 
model all interactions corresponding to the finally 
retained covariates. We compared overall survival using a 
naive test based on the comparison of Kaplan–Meier 
estimates of survival. We compared proportions of 
patients achieving responses and disease control in the 
two groups using Fisher’s exact test.
We did statistical analyses with the SAS software, 
version 9.4. This trial is registered with ClinicalTrials.gov, 
number NCT01655693.
Role of the funding source
The funder was involved in study design, data collection, 
analysis, and interpretation, and writing of the report. 
Data management was done by Lincoln Pharmaceuticals 
and Aixial and statistical analyses were done by Chiltern 
International, both supervised by eXYSTAT. All authors 
had full access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
541 patients were screened between June 15, 2012, and 
Jan 27, 2017, and 144 were excluded because they did not 
meet eligibility criteria. 397 patients were randomly 
assigned to either the 30 mg/m² group (n=133), the 
20 mg/m² group (n=130), or the control group (n=134) 
and included in ITT analysis (figure 1). 376 (95%) 
patients started treatment (120 in the 30 mg/m² group, 
122 in the 20 mg/m² group, and 134 in the control group) 
and comprised the safety population. Of the patients 
who started treatment, 113 (94%) of 120 receiving 
30 mg/m² doxorubicin­loaded nanoparticles, 118 (97%) 
of 122 receiving 20 mg/m² doxorubicin­loaded nano­
particles, and 130 (97%) of 134 patients in the control 
group discontinued study treatment. The most common 
reason for discontinuation was radiological progression 
(77 [68%] of 113 in the 30 mg/m² group, 91 [77%] of 118 in 
the 20 mg/m² group, and 58 [45%] of 130 in the control). 
The mean treatment duration was 3·7 months (SD 3·9) 
in the 30 mg/m² group, 3·4 months (3·9) in the 
20 mg/m² group, and 3·0 months (2·6) in the control 
group. In both experimental groups, the mean number 
of cycles was 4·6 (SD 4·0); 64 (26%) of 244 patients who 
received their allocated intervention delayed at least one 
treatment cycle, and 17 (7%) patients had at least 
one dose reduction; the mean dose­intensity of 
doxorubicin­loaded nanoparticles was 99% (SD 7). In the 
control group, 55 (41%) of 134 patients received only best 
supportive care whereas 79 (59%) were administered a 
systemic anticancer therapy considered as the best 
standard of care by the investigator, the most common of 
which was oxaliplatin plus gemcitabine in 37 (28%) 
patients (appendix p 12).
At the cutoff date for the final analysis (May 28, 2017), 
median follow­up was 22·7 months (IQR 11·2–34·9) and 
288 (73%) of the 397 randomised patients had died 
(99 [74%] of 133 in the 30 mg/m² group; 97 [75%] of 130 in 
the 20 mg/m² group; and 92 [69%] of 134 in the control 
group). Baseline demographics were similar between the 
pooled experimental groups and the control group (table 1). 
Median previous time on sorafenib was 4·1 months 
(IQR 2·4–9·3) in the pooled doxorubicin group and 
4·9 months (2·6–8·7) in the control group. About a quarter 
of patients received additional systemic treatment lines 
after sorafenib and before RELIVE inclusion. Treatments 
received after withdrawal from RELIVE are shown in the 
appendix (p 11).
There was no significant difference in overall survival 
between the groups in the ITT population; median 
overall survival was 9·1 months (95% CI 8·1–10·4) in the 
pooled doxorubicin­loaded nanoparticle group and 
9·0 months (7·1–11·8) in the control group (HR 1·00 
[95% CI 0·78–1·28], two­sided p=0·99; figure 2A). In 
exploratory analyses, overall survival since start of 
sorafenib was also not significantly different between the 
groups, (HR 1·04 [95% CI 0·81–1·32], p=0·77). Overall 
survival in the Child–Pugh A subpopulation was also 
similar between groups: median overall survival was 
10·1 months (95% CI 8·8–11·6) in the pooled 
experimental group and 10·7 months (7·2–12·4) in the 










































Hazard ratio=0·95 (95% Cl 0·74–1·22); 
two-sided p=0·70
Figure 4: Kaplan–Meier analysis of progression-free survival in the intention-to-treat population
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figure 2B). No differences in overall survival were noted 
in any of the predefined subgroups (figure 3).
Median progression­free survival was 2·3 months 
(95% CI 2·1–2·6) in the pooled experimental group and 
2·3 months (2·1–2·8) in the control group (HR 0·95 
[95% CI 0·74–1·22], two­sided p=0·70; figure 4). 
Progression­free survival in the Child–Pugh A sub­
population was also similar between groups (median 
2·4 months [95% CI 2·2–2·8] in the pooled doxorubicin 
group and 2·4 months [2·1–2·8] in the control group). 
No differences in progression­free survival were noted in 
any of the predefined subgroups (figure 5). Results were 
similar for progression­free survival per investigator 
assessment (appendix p 9).
In other exploratory analyses, time to progression by 
independent central review showed similar results, with 
an HR of 0·96 (95% CI 0·74–1·23; two­sided p=0·74; 
appendix p 10) and a median time to progression of 
2·3 months (95% CI 2·1–2·6) in the pooled group and 
2·3 months (2·1–2·8) in the control group.
Independent imaging central review was possible in 
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   ≥65
Sex
   Women
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Geographical region
   Europe or USA
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Race
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   Other
ECOG performance status
   0
   >0
Child–Pugh
   A
   B
Macroscopic vascular invasion
   No
   Yes
Extrahepatic spread
   Yes
Intrahepatic spread
   Yes
Alpha-fetoprotein concentration, ng/mL
   ≥400
   <400
Number of previous treatments
   1
   >1
Anticancer therapy
   Yes
Last reason for sorafenib discontinuation
   Progression
   Intolerance
Previous sorafenib within 10 weeks*
   Yes
Alcohol use
   Yes
Hepatitis C virus
   Yes
Non-alcoholic steatohepatitis
   Yes
Hepatitis B virus
   Yes
Treatment group
   Doxorubicin 20 mg/m²
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Figure 5: Forest plot of progression-free survival in predefined subgroups
*Exposure for at least 20 days at a concentration of at least 400 mg and discontinuation less than 10 weeks before randomisation. ECOG=Eastern Cooperative Oncology Group. n=events. N=group 
size. NE=not estimable.
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263 patients in the pooled doxorubicin­loaded nano­
particles group and 72 [54%] of 134 in the control group; 
table 2). Review was not possible for 121 patients because 
of absence of imaging data (n=29), poor quality imaging 
or identification issues (n=11), and presence of baseline 
imaging but no follow­up imaging (n=81). Among those 
with available data, the proportion of patients achieving an 
objective response or disease control was similar in both 
groups, by both independent and investigator review 
(table 2). In the Child–Pugh A subpopulation, response 
were also similar between the groups (no patients achieved 
a complete response in either group, partial response in 
two [1%] of 179 in the pooled doxorubicin group vs one [2%] 
of 64 in the control group, stable disease in 72 [40%] vs 
28 [44%], and progressive disease in 105 [59%] vs 35 [55%]).
227 (94%) of 242 patients in the pooled doxorubicin­
loaded nanoparticles group and 100 (75%) of 134 patients 
in the control group had at least one treatment­emergent 
adverse event (table 3). These were deemed related to the 
study drug in 177 (73%) patients in the pooled doxorubicin 
group and 58 (43%) of the patients in the control group. 
Serious adverse events occurred in 74 (31%) patients 
receiving doxorubicin­loaded nano particles and 48 (36%) 
in the control group, and were attributed to the study 
drug in 31 (13%) cases in the doxorubicin group and 
13 (10%) in the control group. The most common grade 3 
or 4 drug­related treatment­emergent adverse events 
were asthenia (six [3%] of 242 patients) and neutropenia 
(25 [10%]) in the pooled doxorubicin group and asthenia 
(four [3%] of 134), neutropenia (eight [6%]), and thrombo­
cytopenia (ten [7%]) in the control group. Neutropenia 
was more frequent in those treated with doxorubicin­
loaded nanoparticles than in those in the control group; 
by contrast, thrombocytopenia was less common in those 
treated with doxorubicin­loaded nanoparticles than in 
those in the control group (table 3).
Cardiorespiratory toxicity was rare and not severe for 
most patients treated with doxorubicin­loaded nano­
particles. Asymptomatic decreases of left ventricular 
ejection fraction below 50% occurred in five (2%) of 
242 patients; respiratory symptoms in 11 (5%); and 
oxygen desaturation in 31 (13%), which led to interruption 
or reduction of the speed of perfusion in 13 (5%) patients.
Few drug­related treatment­emergent adverse events 
led to dose reduction (six [2%] of 242 patients treated with 
doxorubicin­loaded nanoparticles vs 22 [16%] of 134 in the 
control group), dose delay (45 [19%] vs 24 [18%]), study 
withdrawal (24 [10%] vs 12 [9%]), or death (six [2%] vs 
one [1%]; appendix pp 13, 15). No difference in the median 
time to deterioration of Child–Pugh score from baseline 
was noted between those treated with doxorubicin­loaded 
nanoparticles (8·1 months [IQR 2·6–not reached]) and 
those in the control group (6·4 months [2·4–not reached]). 
More patients given 30 mg/m² doxorubicin­treated nano­
particles had drug­related treatment­emergent adverse 
events (98 [82%]) than those given than 20 mg/m² 
(79 [65%]; p=0·003) but it did not affect the continuity of 
the trial in terms of treatment­emergent adverse events 
leading to study withdrawal or death (appendix pp 14, 15).
Discussion
The absence of more effective therapies for hepatocellular 
carcinoma is an unmet clinical need; however, chemo­
therapy has been clearly shown to be ineffective and toxic 
in patients with advanced disease. In this phase 3 trial 
assessing doxorubicin­loaded nanoparticles as subsequent­
line treatment for patients in whom sorafenib has failed, 
no difference was detected between doxorubicin­loaded 
nanoparticles and control in terms of overall survival.
Survival in patients with hepatocellular carcinoma is 
influenced by many factors related not only to 
tumour burden but also to underlying liver conditions, 
and minor imbalances in prognostic factors can have a 
meaningful effect on overall survival. Nonetheless, 
baseline characteristics were similar between the groups 
and thus are not a possible explanation for these results. 
One explanation could be insufficient power, because 
patients with a better prognosis than in previous trials 
were enrolled.9,13 Indeed, median overall survival in the 
control group was unexpectedly high in the whole 
population (9·0 months [95% CI 7·1–11·8]) as well as in 
the subpopulation of patients with Child–Pugh score A 
(10·7 months [7·2–12·4]). By contrast, median overall 
survival results in the Child–Pugh A populations of other 
phase 3 trials such as SHARP2 (sorafenib) and RESORCE4 
(regorafenib) were lower: median overall survival was 
7·9 months in the control group of both studies, and was 
8·0 months in the cabozantinib trial.6 Equivalent data were 
observed for overall survival in the control groups of other 
phase 3 trials of drugs being tested after failure of 
sorafenib: in the brivanib trial it was 8·2 months,13 
7·3 months in the trial of everolimus,14 and 7·6 months in 
the REACH trial of ramucirumab;8 overall survival in the 
control group in a phase 3 study of tivantinib was 
9·1 months.9 In the RELIVE trial, only three­quarters of 
patients had previously received only sorafenib as systemic 
treatment whereas a quarter had received at least two lines 
of treatment (sorafenib plus one or more additional lines). 
Thus, the RELIVE trial might have selected patients with 










Complete response 0 0 0 0
Partial response 2 (1%) 1 (1%) 6 (3%) 4 (5%)
Stable disease 80 (39%) 31 (43%) 112 (51%) 41 (53%)
Progressive disease 121 (59%) 40 (56%) 101 (46%) 33 (42%)
Objective response 2 (1%) 1 (1%) 6 (3%) 4 (5%)
Disease control 82 (40%) 32 (44%) 118 (54%) 45 (58%)
Table 2: Objective responses in evaluable patients by independent central review and per investigator 
review
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the most indolent hepatocellular carcinomas, with good 
ECOG performance statuses (0–1) and acceptable liver 
functions (Child–Pugh A5–B7), and a tumour burden 
small enough to keep the patients alive after several lines 
of systemic treatment before randomisation in RELIVE. 
Indeed, the patients with the most aggressive forms of 
hepatocellular carcinoma might have either died during 
the previous systemic lines or did not meet the eligibility 
criteria to enter RELIVE because of end­stage liver disease.
Another possible explanation for the failure to detect a 
treatment difference in the RELIVE study is based on 
the fact that all the phase 3 trials used a placebo as the 
control group, whereas the control group in our trial was 
standard treatment, at the decision of each principal 
investigator. In our control group, although 55 (41%) of 
134 patients received only best supportive care, 
79 (59%) received a systemic anticancer therapy, of 
whom 37 (47%) were given gemcitabine plus oxaliplatin 
(GEMOX). It is possible that GEMOX might be of 
benefit for patients with hepato cellular carcinoma, thus 
concealing the potential benefit of doxorubicin­loaded 
nanoparticles. Data from phase 3 randomised controlled 
trials using GEMOX in advanced hepatocellular 
carcinoma are still needed. In a prospective cohort study 
by Taïeb and colleagues,25 overall survival with GEMOX 
was 12 months and in a phase 2 single­arm study of 
32 patients by Louafi and colleagues,26 it was 11·5 months. 
In addition, in a large multicentre retro spective study 
of 204 patients, overall survival with GEMOX was 
11 months.27 By contrast, overall survival with free doxo­
rubicin was only 4·9 months in a phase 2 randomised 
controlled trial in Asia.28
Furthermore, the antitumour activity of doxorubicin­
loaded nanoparticles might not be strong enough to 
extend survival. This idea is supported by the negative 
findings of the secondary and exploratory endpoints such 
as progression­free survival, objective response, and time 
to progression, as well as subgroup analyses, which all 
clearly show no difference between the 20 mg/m² and the 
30 mg/m² groups. Furthermore, the 30 mg/m² group 
had more patients with drug­related treatment­emergent 
adverse events than the 20 mg/m² group, thus 
demonstrating a dose­dependent toxicity of doxorubicin.
Consistent with previously published data, clinically 
significant (observed in at least 10% of patients) drug­
related treatment­emergent adverse events of any grade 
attributable to doxorubicin were mostly asthenia, nausea, 
vomiting, and neutropenia, whereas thrombo cytopenia 
(probably due to gemcitabine) and par aesthesia (probably 
due to oxaliplatin) were observed in the control group. 
Although acute respiratory distress syndrome occurred in 
some patients due to intrahepatic arterial injection of 
doxorubicin­loaded nanoparticles in the phase 1–2 trial,24 
no clinically significant pulmonary treatment­emergent 
adverse events were observed after 6 h of intravenous 
perfusion in RELIVE. Headache was more prevalent in 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































www.thelancet.com/gastrohep   Published online April 3, 2019   http://dx.doi.org/10.1016/S2468-1253(19)30040-8 11
doxorubicin, which might be specific to the nanoformu­
lation, since this is not commonly reported with free 
doxorubicin, but is reported with other forms of nano­
formulation of doxorubicin such as liposomal doxo­
rubicin.29 Causes of three deaths (in the pooled 
experimental group) considered by investigators and the 
data safety monitoring board to be treatment related were 
not unusual for this patient population (interstitial lung 
disease, lung infection, and peritoneal haemor rhage). Of 
note, only about a tenth of patients in the pooled 
doxorubicin­loaded nanoparticle group withdrew from 
the trial prematurely because of drug toxicity.
In conclusion, this first phase 3 study of doxorubicin­
loaded nanoparticles in patients with advanced hepato­
cellular carcinoma who have already been treated with 
sorafenib did increase overall survival. The results of our 
trial could inform the design of future studies in this 
patient population.
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